Anavex Life Sciences nabs patent win for Alzheimer's candidate

Aug. 31, 2021 10:22 AM ETAnavex Life Sciences Corp. (AVXL)By: Dulan Lokuwithana, SA News Editor12 Comments

Neuron system disease
koto_feja/iStock via Getty Images

  • Anavex Life Sciences (AVXL +5.2%) is trading higher on below-average volume after the website for the United States Patent and Trademark Office (USPTO) indicated a patent granted for the company covering its lead candidate ANAVEX2-73 for Alzheimer’s disease.
  • ANAVEX2-73 is an oral small molecule, undergoing studies for multiple indications, including Alzheimer’s disease and Parkinson’s disease.
  • In July, Anavex (NASDAQ:AVXL) reported promising pre-clinical data for ANAVEX 2-73 to indicate a dose-dependent effect in preventing cognitive impairments in mice.
  • By H2 2022, the company intends to provide top-line data from a Phase 2b/3 clinical trial for ANAVEX 2-73 in patients with Alzheimer’s disease.
  • In mid-August, Anavex (AVXL) had enrolled 509 patients in the randomized, double-blind, placebo-controlled study.

Recommended For You

Comments (12)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.